These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 32018128)

  • 1. Biomarkers for immunotherapy response in head and neck cancer.
    Gavrielatou N; Doumas S; Economopoulou P; Foukas PG; Psyrri A
    Cancer Treat Rev; 2020 Mar; 84():101977. PubMed ID: 32018128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
    Szturz P; Vermorken JB
    BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions.
    Rothschild U; Muller L; Lechner A; Schlösser HA; Beutner D; Läubli H; Zippelius A; Rothschild SI
    Swiss Med Wkly; 2018; 148():w14625. PubMed ID: 29756633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives.
    Samra B; Tam E; Baseri B; Shapira I
    J Investig Med; 2018 Oct; 66(7):1023-1030. PubMed ID: 29941547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 10. Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
    Economopoulou P; Kotsantis I; Psyrri A
    Curr Treat Options Oncol; 2016 Aug; 17(8):40. PubMed ID: 27315066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for recurrent/metastatic head and neck cancer.
    Alfieri S; Cavalieri S; Licitra L
    Curr Opin Otolaryngol Head Neck Surg; 2018 Apr; 26(2):152-156. PubMed ID: 29432222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
    Muratori L; La Salvia A; Sperone P; Di Maio M
    Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogression].
    Brix N; Dunn L; Seiwert T; Belka C; Lauber K
    Internist (Berl); 2020 Jul; 61(7):682-689. PubMed ID: 32462252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for head and neck cancer: Recent advances and future directions.
    Cramer JD; Burtness B; Ferris RL
    Oral Oncol; 2019 Dec; 99():104460. PubMed ID: 31683169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
    Przybylski K; Majchrzak E; Weselik L; Golusiński W
    Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.